Foley Hoag LLP recently advised global biopharmaceutical company Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a partnership with Complement Pharma to co-develop a pre-clinical C6 complement inhibitor for…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
